Simplex Trading, LLC Revolution Medicines, Inc. Transaction History

Simplex Trading, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 25, 2024	BUY	$30.14 - $40.68 $231,927 - $313,032	7,695 Added 79.75%	17,344 $673,000
Q1 2024 Apr 25, 2024	BUY	$26.56 - $33.55 $30,464 - $38,481	1,147 Added 13.49%	9,649 $310,000
Q4 2023 Feb 02, 2024	BUY	$18.35 - $34.12 $156,011 - $290,088	8,502 New	8,502 $243,000
Q2 2023 Aug 04, 2023	SELL	$20.28 - $27.0 $60 - $81	-3 Reduced 0.91%	328 $8,000
Q1 2023 Apr 27, 2023	SELL	$20.76 - $30.09 $27,735 - $40,200	-1,336 Reduced 80.14%	331 $7,000
Q4 2022 Feb 02, 2023	BUY	$17.68 - $25.53 $4,879 - $7,046	276 Added 19.84%	1,667 $39,000
Q3 2022 Nov 04, 2022	BUY	$17.46 - $26.0 $23,396 - $34,840	1,340 Added 2627.45%	1,391 $27,000
Q2 2022 Aug 03, 2022	SELL	$14.54 - $27.17 $8,724 - $16,302	-600 Reduced 92.17%	51 $0
Q1 2022 May 02, 2022	SELL	$17.31 - $26.4 $7,252 - $11,061	-419 Reduced 39.16%	651 $16,000
Q2 2021 Aug 12, 2021	BUY	$29.0 - $47.44 $31,030 - $50,760	1,070 New	1,070 $33,000
Q1 2021 Apr 26, 2021	SELL	$37.21 - $54.43 $26,084 - $38,155	-701 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$30.19 - $45.49 $21,163 - $31,888	701 New	701 $27,000

266

161M

260K

620K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.8B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Simplex Trading, LLC with notifications on news.